Protocol Ledger

NCT04840199 · Phase II · TERMINATED

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus It

Interventional Phase II clinical trial protocol NCT04840199 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-19 Enrollment: 44 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04840199
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)44 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04840199
Protocol FieldVerified Registry Value
NCT IdentifierNCT04840199
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment44 participants (ACTUAL)
Registered Start Date2022-04-19
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI